ArticleBMC cancer2017
Metabolic dysregulation and cancer mortality in a national cohort of blacks and whites.
Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ethnic differences in metabolic syndrome in high-income countries: A systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2024Pooled it
- 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.Circulation · 2025Review
- The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study.BMC public health · 2025Article
- Metabolic syndrome and cardiovascular disease among adult cancer patients: results from NHANES 2007-2018.BMC public health · 2024Article
- Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.BMC medicine · 2024Article
- Metabolic basis of cardiac dysfunction in cancer patients.Current opinion in cardiology · 2024Review
- 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.Circulation · 2024Review
- Long-term outcomes of esophageal and gastric cancer patients with cardiovascular and metabolic diseases: A two-center propensity score-matched cohort study.Journal of translational internal medicine · 2023Article
- Nonrestorative sleep is a risk factor for metabolic syndrome in the general Japanese population.Diabetology & metabolic syndrome · 2023Article
- Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.Circulation · 2023Review
- INPP4B protects from metabolic syndrome and associated disorders.Communications biology · 2021Article
- Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.Circulation · 2021Article
- Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative.Cancer · 2021Article
- Obesity and overall mortality: findings from the Jackson Heart Study.BMC public health · 2021Article
- Obesity and the Bidirectional Risk of Cancer and Cardiovascular Diseases in African Americans: Disparity vs. Ancestry.Frontiers in cardiovascular medicine · 2021Review
- Construction and Analysis of Human Diseases and Metabolites Network.Frontiers in bioengineering and biotechnology · 2020Article
- The effect of metabolic risk factors on cancer mortality among blacks and whites.Translational cancer research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWe examined the association between metabolic dysregulation and cancer mortality in a prospective cohort of Black and White adults.
methodsA total of 25,038 Black and White adults were included in the analysis. Metabolic dysregulation was defined in two ways: 1) using the joint harmonized criteria for metabolic syndrome (MetS) and 2) based on factor analysis of 15 variables characterizing metabolic dysregulation. We estimated hazards ratios (HRs) and 95% confidence intervals (CIs) for the association of MetS and metabolic dysregulation with cancer mortality during follow-up using Cox proportional hazards models.
resultsAbout 46% of Black and 39% of White participants met the criteria for MetS. Overall, participants with MetS (HR: 1.22, 95% CI: 1.03-1.45) were at increased risk of cancer-related death. In race-stratified analysis, Black participants with MetS had significantly increased risk of cancer mortality compared with those without MetS (HR: 1.32, 95% CI: 1.01-1.72), increasing to more than a 2-fold risk of cancer mortality among those with five metabolic syndrome components (HR: 2.35, 95% CI: 1.01-5.51).
conclusionsThere are marked racial differences in the prevalence of metabolic dysregulation defined as MetS based on the harmonized criteria. The strong positive associations between MetS and cancer mortality suggests that efforts to improve cancer outcomes in general, and racial disparities in cancer outcomes specifically, may benefit from prevention and management of MetS and its components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.